Sector Gamma AS lessened its position in shares of Humana Inc (NYSE:HUM) by 34.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,999 shares of the insurance provider’s stock after selling 22,901 shares during the period. Humana makes up about 1.9% of Sector Gamma AS’s portfolio, making the stock its 20th largest holding. Sector Gamma AS’s holdings in Humana were worth $11,249,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of HUM. Maverick Capital Ltd. lifted its stake in Humana by 150.9% in the 2nd quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock valued at $411,408,000 after purchasing an additional 932,778 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in Humana by 4,141.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 706,911 shares of the insurance provider’s stock valued at $187,543,000 after purchasing an additional 690,246 shares during the last quarter. PointState Capital LP bought a new position in Humana in the 2nd quarter valued at approximately $180,507,000. Marshall Wace North America L.P. lifted its stake in Humana by 6,921.1% in the 2nd quarter. Marshall Wace North America L.P. now owns 536,275 shares of the insurance provider’s stock valued at $142,273,000 after purchasing an additional 528,637 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Humana in the 2nd quarter valued at approximately $115,680,000. 92.93% of the stock is owned by institutional investors.
In other news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now directly owns 12,994 shares in the company, valued at $3,764,361.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.54% of the company’s stock.
NYSE HUM traded up $2.44 on Friday, hitting $317.58. The company’s stock had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. Humana Inc has a 1-year low of $225.65 and a 1-year high of $342.03. The company’s 50-day moving average is $277.48 and its 200 day moving average is $270.93. The firm has a market cap of $39.82 billion, a PE ratio of 21.83, a PEG ratio of 1.27 and a beta of 0.85.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a net margin of 4.13% and a return on equity of 22.47%. The firm had revenue of $16.24 billion during the quarter, compared to analysts’ expectations of $16.15 billion. During the same period in the prior year, the company posted $4.58 EPS. The company’s revenue was up 14.3% on a year-over-year basis. On average, equities analysts expect that Humana Inc will post 17.75 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Monday, December 30th. Humana’s dividend payout ratio (DPR) is presently 15.12%.
Several equities analysts recently commented on HUM shares. Morgan Stanley dropped their price objective on shares of Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a research note on Thursday, September 26th. BMO Capital Markets downgraded shares of Humana from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $345.00 to $290.00 in a research note on Monday, September 30th. Mizuho started coverage on shares of Humana in a research note on Thursday, October 17th. They issued a “buy” rating and a $316.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, UBS Group increased their price objective on shares of Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $322.63.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Ex-Dividend
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.